지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2016.1
- 수록면
- 351 - 355 (5page)
이용수
초록· 키워드
오류제보하기
Afatinib is an oral tyrosine kinase inhibitor (TKI) that inhibit Endothelial Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), and HER4. The common side effects of EGFR TKI are rash, acne, di-arrhea, stomatitis, pruritus, nausea, and loss of appetite. Drug induced pneumonitis is the less common adverse ef-fects of EGFR TKI. Afatinib, 2nd generation EGFR TKI is anticipated to overcome drug resistance from 1st genera-tion EGFR TKI according to preclinical study, and several studies are being conducted to compare clinical efficacy between 1st and 2nd EGFR TKI. Several cases of rug induced acute fatal pneumonitis were reported after use of er-lotinib or gefitinib. However, a case of acute fatal pneumonitis associated with afatinib was note reported except drug induced pneumonitis in other clinical study. Here, we present a cases of acute severe pneumonitis related with afatinib in metastatic lung adenocarcinoma with literature review.
목차
등록된 정보가 없습니다.
참고문헌 (10)
참고문헌 신청
Pao W / 2005 / Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain / PLoS Med 2:e73
Soria JC / 2015 / Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial / Lancet Oncol 16:897~907
Yang JC / 2012 / Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial / Lancet Oncol 13:539~548
Zhang Y / 2012 / Successful treatment of gefitinib-induced acute interstitial pneumonitis with corticosteroid and non-invasive BIPAP-ventilation / J Thorac Dis 4:316~319
Lai YC / 2011 / Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review / Int J Clin Pharmacol Ther 49:461~466
Soria JC / 2015 / Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial / Lancet Oncol 16:897~907
Yang JC / 2012 / Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial / Lancet Oncol 13:539~548
Zhang Y / 2012 / Successful treatment of gefitinib-induced acute interstitial pneumonitis with corticosteroid and non-invasive BIPAP-ventilation / J Thorac Dis 4:316~319
Lai YC / 2011 / Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review / Int J Clin Pharmacol Ther 49:461~466
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Tuberculosis and Respiratory Diseases
2017 .01
-
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Cancer Research and Treatment
2020 .01
-
Meta-analysis of Seven Randomized Control Trials to Assess the Efficacy and Toxicity of Combining EGFR-TKI with Chemotherapy for Patients with Advanced NSCLC who Failed First-Line Treatment
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
Journal of Pathology and Translational Medicine
2016 .01
-
Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
Tuberculosis and Respiratory Diseases
2019 .01
-
Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-induced Pneumonitis
Cancer Research and Treatment
2021 .01
-
COVID-19, A and Hypersensitivity Pneumonitis
Infection and Chemotherapy
2020 .01
-
COVID-19 Vaccine-Associated Pneumonitis in the Republic of Korea: A Nationwide Multicenter Survey
Journal of Korean Medical Science
2023 .04
-
Low-dose Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Clinical Characteristics and Continued Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Administration in EGFR-Mutated Non-small Cell Lung Cancer with Skeletal Metastasis
Cancer Research and Treatment
2016 .01
-
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
Journal of Pathology and Translational Medicine
2019 .01
-
Reply: COVID-19, A and Hypersensitivity Pneumonitis
Infection and Chemotherapy
2020 .01
-
COVID-19, A Clinical Syndrome Manifesting as Hypersensitivity Pneumonitis
Infection and Chemotherapy
2020 .01
-
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
Cancer Research and Treatment
2017 .01
-
Gefitinib에 내성을 보인 폐선암에서 발견된Epidermal Growth Factor Receptor 돌연변이 양성인 소세포폐암
대한내과학회지
2015 .01
-
EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
Cancer Research and Treatment
2018 .01
-
Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
Cancer Research and Treatment
2023 .01
-
Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance
Journal of Pathology and Translational Medicine
2018 .01
-
Hypersensitivity Pneumonitis Caused by Cephalosporins With Identical R1 Side Chains
Allergy, Asthma & Immunology Research
2015 .01
-
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Cancer Research and Treatment
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0